Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system.

Prostate cancer is the second most common cause of cancer death in American men and represents a significant factor in US health care costs. Radiation therapy serves as one of the most effective treatments for prostate cancer. However, radiation is also an expensive treatment modality and is a significant contributor to the overall rise in the cost of prostate cancer care. Currently, standard external beam radiation therapy for prostate cancer consists of between 75.6 and 81.0 Gy of radiation separated into 1.8- to 2-Gy doses (or "fractions") given daily for between 7 and 9 weeks. Recently, relatively shorter treatment schedules delivering more radiation per treatment-consisting of fractions > 2 Gy-over shorter time periods have been proposed in an effort to curtail rising health care costs and improve patient convenience. However, significant uncertainty still remains regarding outcomes from this type of more condensed treatment, known as"hypofractionated"radiation. In this article, we provide the historical background and rationale for hypofractionated prostate cancer treatment, discuss the potential benefits and risks of prostate hypofractionation, and review the clinical evidence regarding the effectiveness of hypofractionated radiation therapy for prostate cancer.

[1]  I. Kaplan,et al.  Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinoma , 2012, Cancer.

[2]  C. Gross,et al.  Geographic analysis of the radiation oncology workforce. , 2012, International journal of radiation oncology, biology, physics.

[3]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[4]  J. Fowler,et al.  Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. , 2011, International journal of radiation oncology, biology, physics.

[5]  R. Stoyanova,et al.  Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer , 2011 .

[6]  M. Ritter,et al.  Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence , 2011, Cancer.

[7]  B. Kavanagh,et al.  Back to the future: a proton pro/con. , 2011, Oncology.

[8]  Moyed Miften,et al.  Advances in Treatment Techniques: Stereotactic Body Radiation Therapy and the Spread of Hypofractionation , 2011, Cancer journal.

[9]  S. Lipsitz,et al.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Fritz H Schröder,et al.  Prostate cancer around the world. An overview. , 2010, Urologic oncology.

[11]  F. Zhu,et al.  Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial , 2010 .

[12]  A. Pont,et al.  Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Lidia Strigari,et al.  A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[14]  Y. Lievens.  Hypofractionated breast radiotherapy: financial and economic consequences. , 2010, Breast.

[15]  B. Hickey,et al.  Hypofractionated Whole‐Breast Radiotherapy: Impact on Departmental Waiting Times and Cost , 2010, Journal of medical imaging and radiation oncology.

[16]  Y. Kwok,et al.  Update on radiation-based therapies for prostate cancer , 2010, Current opinion in oncology.

[17]  A. Biete,et al.  Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[18]  M. Ritter.  Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. , 2008, Seminars in radiation oncology.

[19]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[20]  M. Ritter,et al.  Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. , 2008, International journal of radiation oncology, biology, physics.

[21]  E. Noordijk,et al.  Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. , 2006, Journal of the National Cancer Institute.

[22]  W. J. Morris,et al.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Kievit,et al.  Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. , 2003, Journal of the National Cancer Institute.

[24]  C. Dardoufas,et al.  A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC): effective palliation and patients' convenience. , 2002, Lung cancer.

[25]  P. Taylor,et al.  Molecular pathology of breast cancer , 2000, Breast Cancer Research.

[26]  A. Kiss,et al.  Clinical Investigation : Genitourinary Cancer Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer , 2012 .

[27]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. , 2012, The Lancet. Oncology.

[28]  M. Bremer.  [Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer]. , 2012, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].